Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Bicalutamide in AR+, HER2- Metastatic Breast Cancer
NCT05095207Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Sep 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in breast cancer, sponsored by Icahn School of Medicine at Mount Sinai. Started Sep 2021; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05095207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095207.